Amgen Faces EU Withdrawal of Tavneos Therapy for Rare Disorder
0h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
amgentavneoseuropean-medicines-agency
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Amgen received notification on 26 June 2026 that the Committee for Medicinal Products for Human Use recommended withdrawal of marketing authorization for Tavneos (avacopan) from the European Union. The negative opinion from the European Medicines Agency's key scientific committee follows a review under Article 20 of Regulation (EC) No 726/2004. Tavneos is an approved treatment for ANCA-associated vasculitis, a rare autoimmune disorder affecting small blood vessels. The therapy generated $380 million in global revenue for Amgen during the last fiscal year.
Regulatory scrutiny of rare disease therapies has intensified across major markets. In October 2025, the FDA issued a complete response letter for Sobi's myelofibrosis treatment pelacarsen, citing insufficient long-term data. The European Medicines Agency has demonstrated increased vigilance regarding post-marketing requirements for conditionally approved medications.
The current biotech landscape faces pressure from both regulatory bodies and cost-conscious payers. The iShares Nasdaq Biotechnology ETF (IBB) has declined 4.2% year-to-date amid sector rotation toward value stocks. Ten-year Treasury yields at 4.31% have reduced investor appetite for long-duration biotech assets.
The CHMP review represents a standard procedure for medications that received conditional approval. Tavneos secured EU approval in January 2022 based on Phase III data demonstrating superiority over standard steroid therapy. The committee's negative opinion suggests concerns regarding post-approval confirmatory evidence or safety monitoring requirements.
Tavneos generated $380 million in worldwide revenue during Amgen's most recent fiscal year. The therapy achieved quarterly sales growth of 22% year-over-year in Q1 2026. European markets accounted for approximately 35% of Tavneos' global revenue, representing $133 million annually.
Amgen's market capitalization stands at $148 billion following a 2.1% decline in after-hours trading. The company acquired Tavneos through its $3.7 billion acquisition of ChemoCentryx in October 2022. Tavneos represented approximately 12% of Amgen's inflammation franchise revenue.
Before/After EU Revenue Projection:
The therapy's performance contrasts with Johnson & Johnson's Simponi, which generated $2.1 billion in annual EU revenue for rheumatoid arthritis. Rare disease therapies typically command premium pricing, with Tavneos costing approximately €120,000 annually per patient in European markets.
The regulatory setback creates immediate headwinds for Amgen's growth narrative in international markets. Tavneos represented one of the company's most promising near-term revenue drivers outside its mature oncology portfolio. Analysts project a 3-5% downward revision to Amgen's 2027-2028 revenue estimates, potentially lowering EPS projections by €0.45-€0.60.
Competitive therapies stand to benefit from reduced treatment options in the EU vasculitis market. GlaxoSmithKline's Nucala (mepolizumab) and ChemoCentryx's earlier-stage portfolio could experience increased investor interest. The XBI biotech ETF faces technical pressure near its 200-day moving average of $85.42.
A counter-argument suggests the impact may be limited given Tavneos remains approved in United States markets. The FDA has not indicated any review of Tavneos' approval status, and US revenue represents the majority of the drug's sales. American patients account for approximately 65% of global ANCA-associated vasculitis treatment revenue.
Institutional flow data indicates hedge funds increased short exposure to mid-cap biotech names by 18% in the week preceding the decision. Credit default swaps on Amgen bonds widened 2 basis points following the announcement, though the company maintains an A3 investment grade rating.
Amgen will request a re-examination of the CHMP opinion within 15 days of the 26 June notification. The final decision by the European Commission typically follows within 67 days of a negative opinion, placing a final ruling in early September 2026.
The company's Q2 2026 earnings call on 29 July will provide updated guidance regarding Tavneos' commercial prospects. Management commentary on alternative regulatory pathways or additional data submissions will be scrutinized by analysts.
Technical levels for Amgen stock show support at $265, representing the 100-day moving average. Resistance sits at $285, near the stock's pre-announcement closing price. Options markets imply a 3.2% daily move following the earnings announcement.
Watch for regulatory decisions on competing vasculitis therapies, including Otsuka's Tavlesse marketing authorization application scheduled for Q3 2026 review. The FDA's orphan drug division has six rare disease therapy reviews scheduled through December 2026.
Tavneos (avacopan) is a complement C5a receptor inhibitor approved for treating ANCA-associated vasculitis, a rare condition causing inflammation and damage to small blood vessels. The therapy received conditional approval based on the ADVOCATE trial showing 65.7% of patients achieved sustained remission at 52 weeks compared to 54.9% with standard steroid therapy. The drug works by targeting a specific inflammatory pathway without broad immunosuppression.
The Tavneos review follows pattern of increased regulatory scrutiny post-approval. In 2025, Bayer's cardiomyopathy treatment Vericiguat received a negative CHMP opinion despite US approval, ultimately reversed after additional data submission. The EMA has withdrawn 12 conditional approvals since 2020, with 8 reversals upon re-examination. Rare disease therapies account for approximately 40% of conditional marketing authorizations in the EU.
Amgen's dividend yield of 3.2% appears secure despite the Tavneos setback. The company generates approximately $9 billion annually in free cash flow and has maintained dividend growth for 12 consecutive years. Tavneos represents less than 2% of total revenue, with the osteoporosis drug Prolia generating $4.1 billion annually and cardiovascular treatment Repatha contributing $1.8 billion.
The CHMP recommendation challenges Amgen's $3.7 billion acquisition thesis while demonstrating increased EU regulatory rigor.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.